Evidence map›Paper›PMID 26098457›Full record

ArticleRadiology2015

Incidence of Internal Mammary Lymph Nodes with Silicone Breast Implants at MR Imaging after Oncoplastic Surgery.

Elizabeth J Sutton, Elizabeth J Watson, Girard Gibbons, Debra A Goldman, Chaya S Moskowitz, Maxine S Jochelson, D David Dershaw, Elizabeth A Morris

Open access · greenAbstract read
In one paragraph

Article in Radiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Management of MRI-Detected Benign Internal Mammary Lymph Nodes.The Indian journal of radiology & imaging · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Elizabeth J SuttonFrom the Department of Radiology (E.J.S., E.J.W., G.G., M.S.J., D.D.D., E.A.M.) and Department of Epidemiology & Biostatistics (D.A.G., C.S.M.), Memorial Sloan-Kettering Cancer Center, 300 E 66th St, Suite 715, New York, NY 10065.
Elizabeth J WatsonFrom the Department of Radiology (E.J.S., E.J.W., G.G., M.S.J., D.D.D., E.A.M.) and Department of Epidemiology & Biostatistics (D.A.G., C.S.M.), Memorial Sloan-Kettering Cancer Center, 300 E 66th St, Suite 715, New York, NY 10065.
Girard GibbonsFrom the Department of Radiology (E.J.S., E.J.W., G.G., M.S.J., D.D.D., E.A.M.) and Department of Epidemiology & Biostatistics (D.A.G., C.S.M.), Memorial Sloan-Kettering Cancer Center, 300 E 66th St, Suite 715, New York, NY 10065.
Debra A GoldmanFrom the Department of Radiology (E.J.S., E.J.W., G.G., M.S.J., D.D.D., E.A.M.) and Department of Epidemiology & Biostatistics (D.A.G., C.S.M.), Memorial Sloan-Kettering Cancer Center, 300 E 66th St, Suite 715, New York, NY 10065.
Chaya S MoskowitzFrom the Department of Radiology (E.J.S., E.J.W., G.G., M.S.J., D.D.D., E.A.M.) and Department of Epidemiology & Biostatistics (D.A.G., C.S.M.), Memorial Sloan-Kettering Cancer Center, 300 E 66th St, Suite 715, New York, NY 10065.
Maxine S JochelsonFrom the Department of Radiology (E.J.S., E.J.W., G.G., M.S.J., D.D.D., E.A.M.) and Department of Epidemiology & Biostatistics (D.A.G., C.S.M.), Memorial Sloan-Kettering Cancer Center, 300 E 66th St, Suite 715, New York, NY 10065.
D David DershawFrom the Department of Radiology (E.J.S., E.J.W., G.G., M.S.J., D.D.D., E.A.M.) and Department of Epidemiology & Biostatistics (D.A.G., C.S.M.), Memorial Sloan-Kettering Cancer Center, 300 E 66th St, Suite 715, New York, NY 10065.
Elizabeth A MorrisFrom the Department of Radiology (E.J.S., E.J.W., G.G., M.S.J., D.D.D., E.A.M.) and Department of Epidemiology & Biostatistics (D.A.G., C.S.M.), Memorial Sloan-Kettering Cancer Center, 300 E 66th St, Suite 715, New York, NY 10065.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeTo assess the incidence of benign and malignant internal mammary lymph nodes (IMLNs) at magnetic resonance (MR) imaging among women with a history of treated breast cancer and silicone implant reconstruction. MATERIALS AND

methodsThe institutional review board approved this HIPAA-compliant retrospective study and waived informed consent. Women were identified who (a) had breast cancer, (b) underwent silicone implant oncoplastic surgery, and (c) underwent postoperative implant-protocol MR imaging with or without positron emission tomography (PET)/computed tomography (CT) between 2000 and 2013. The largest IMLNs were measured. A benign IMLN was pathologically proven or defined as showing 1 year of imaging stability and/or no clinical evidence of disease. Malignant IMLNs were pathologically proven. Incidence of IMLN and positive predictive value (PPV) were calculated on a per-patient level by using proportions and exact 95% confidence intervals (CIs). The Wilcoxon rank sum test was used to assess the difference in axis size.

resultsIn total, 923 women with breast cancer and silicone implants were included (median age, 46 years; range, 22-89 years). The median time between reconstructive surgery and first MR imaging examination was 49 months (range, 5-513 months). Of the 923 women, 347 (37.6%) had IMLNs at MR imaging. Median short- and long-axis measurements were 0.40 cm (range, 0.20-1.70 cm) and 0.70 cm (range, 0.30-1.90 cm), respectively. Two hundred seven of 923 patients (22.4%) had adequate follow-up; only one of the 207 IMLNs was malignant, with a PPV of 0.005 (95% CI: 0.000, 0.027). Fifty-eight of 923 patients (6.3%) had undergone PET/CT; of these, 39 (67.2%) had IMLN at MR imaging. Twelve of the 58 patients (20.7%) with adequate follow-up had fluorine 18 fluorodeoxyglucose-avid IMLN, with a median standardized uptake value of 2.30 (range, 1.20-6.10). Only one of the 12 of the fluorodeoxyglucose-avid IMLNs was malignant, with a PPV of 0.083 (95% CI: 0.002, 0.385).

conclusionIMLNs identified at implant-protocol breast MR imaging after oncoplastic surgery for breast cancer are overwhelmingly more likely to be benign than malignant. Imaging follow-up instead of immediate metastatic work-up may be warranted.

Indexed as

Breast ImplantsAdultAgedAged, 80 and overAxillaBreast NeoplasmsDisease ProgressionFemaleFluorodeoxyglucose F18HumansIncidenceLymph Node ExcisionLymph NodesMagnetic Resonance ImagingMammaplastyMastectomyFluorodeoxyglucose F18RadiopharmaceuticalsSilicones

Identifiers

PMID26098457
PMCPMC4976465
OpenAlexW1850032583

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.